Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL February 2025 Clinical trials Read more
2023 January Clinical practice A new and efficient treatment regimen for patients undergoing allogeneic HSCT Read more
2023 January Clinical practice Safety data of lisocabtagene maraleucel supports its use in an outpatient setting Read more
2023 January Pharma News FDA accepts license application of reformulated denileukin diftitox for patients with CTCL Read more
2023 January CongressUpdate Recent exposure to chemotherapy negatively impacts CAR-T cell treatment outcomes Read more
2022 December Clinical trials Impressive response with immuno- plus chemotherapy in patients with Hodgkin’s lymphoma Read more